Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From UCB S.A.
Cosentyx Becomes First Biologic Approved For HS In Nearly A Decade
The Swiss major should have a considerable first-to-market advantage over other IL-17 biologics from the likes of UCB and Acelyrin that are also targeting the hidradenitis suppurativa space.
Stock Watch: Defeat Is The Mother Of Reinvention
Companies that are successful do not need to change their name, therapeutic area or product focus.
Keeping Track: Entasis’ Antibiotic Xacduro, Two Opioid Misuse Therapies Clear US FDA; Pfizer’s Paxlovid Makes It Official
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
UCB Holds Breath Amid Concerns Of Second FDA Rejection Of Bimzelx
The US Food and Drug Administration has published a report after an inspection of UCB’s Belgian facility where Bimzelx is manufactured and the findings suggest that a long-awaited approval for the psoriasis drug should not be taken for granted.
- Research, Analytical Equipment & Supplies
- Antisense, Oligonucleotides
- Large Molecule
Drug Discovery Technologies
- Other Names / Subsidiaries
- Celltech Pharmaceuticals, Inc.
- Element Genomics
- Engage Therapeutics, Inc., Ra Pharmaceuticals, Inc.
- Schwarz Pharma
- UCB Biopharma
- Upstate Pharma, LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.